Veracyte (VCYT) The 44th Annual William Blair Growth Stock Conference summary

Business overview and strategic vision

• Focused on transforming cancer care globally, expanding from endocrinology to a broad portfolio in thyroid, prostate, breast, and lung cancer.

• Over 450,000 patients served in 35+ countries, with tests featured in 500+ publications and 35 clinical trials.

• Core belief that more genomic and clinical data leads to better outcomes, leveraging whole transcriptome and whole genome approaches.

• Diagnostics platform enables repeated cycles of evidence generation, supporting adoption and reimbursement.

• Platform drives market leadership for Afirma (thyroid) and Decipher (prostate), with expansion across the cancer care continuum.

Growth drivers and product updates

• Four key growth drivers: expanding Decipher and Afirma share, launching three new IVD tests in Europe, Percepta Nasal Swab for lung cancer, and MRD test via C2i acquisition.

• Decipher Prostate received highest NCCN guideline rating, with 30% YoY test volume growth and market penetration at 30-35%, aiming for 80%.

• Afirma has helped 175,000+ patients avoid unnecessary surgery, with 14,000 tests and 14% revenue growth in Q1; market penetration at 60%, targeting 80%.

• Continued evidence generation and guideline inclusion drive adoption and payer coverage for both tests.

Innovation and pipeline

• Multi-platform IVD approach with Prosigna manufacturing transferred to France, and upcoming launches for Prosigna, Decipher Prostate (PCR), and Percepta Nasal Swab (NGS) in 2025-2026.

• Percepta Nasal Swab offers non-invasive lung nodule risk assessment, with clinical validation published and utility study underway for reimbursement.

• MRD market entry via C2i acquisition, leveraging whole genome sequencing for sensitive, rapid, and minimally invasive monitoring.

• MRD test differentiates with low blood volume, rapid patient-specific signatures, and broad tumor landscape coverage.